A long winter end—perhaps                      

After years spent in regulatory purgatory, North America’s cannabis industry is suddenly inhaling a heady mix of optimism and speculation. Reports that the United States government may reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act have triggered one of the most violent rallies in cannabis shares since the bubble years of 2020–21. No executive order has yet been signed. But in markets starved of good news, direction often matters more than destination.

The tax code that broke the business

The excitement rests on a dull sounding but transformative piece of tax law. As long as cannabis sits in Schedule I—alongside heroin and other substances deemed to have no medical use—America’s Internal Revenue Code Section 280E applies. This provision denies “plant-touching” cannabis businesses the right to deduct ordinary operating expenses. Rent, wages and marketing costs are all taxed as if they were profits. The result is a fiscal absurdity: effective tax rates of 60–70% on economic earnings are common, turning viable businesses into cash-flow cripples.

Why Schedule III changes the arithmetic

Moving cannabis to Schedule III would not legalise recreational use at the federal level. But it would acknowledge medical value—and, crucially, lift the burden of 280E. With a stroke of the pen, margins would widen, cash flows would improve and balance-sheets might begin to heal, even if revenues remained unchanged. For many multi-state operators (MSOs), the difference between life support and lift-off lies not in sales growth, but in tax deductibility.

Markets smell reform and rush in

Markets, ever keen to anticipate policymakers, reacted with exuberance. Shares of American cannabis firms surged as short-sellers rushed to cover and momentum traders—absent for years—returned in force. Exchange-traded funds tracking U.S. cannabis stocks, notably the AdvisorShares Pure US Cannabis ETF (MSOS), posted some of their strongest sessions on record as investors scrambled to rebuild exposure. More aggressive vehicles magnified the move: leveraged cannabis ETFs delivered eye-catching gains, while also reminding investors that products with daily resets amplify losses just as efficiently as profits when volatility turns.

Canada catches a second-hand high

The exuberance spilled north of the border. Canadian cannabis champions, long battered by overcapacity and anaemic demand at home, also leapt higher. Investors reasoned that a thaw in America’s federal stance might eventually allow firms such as Canopy Growth and Tilray to gain fuller access to the world’s largest cannabis market, whether through acquisitions, partnerships or creative corporate engineering. Even so, today’s prices remain a shadow of the giddy peaks reached during the last great legalisation hype cycle.

A valuation reset, not a revenue boom

Behind the rally lies a more sober recalculation of value. Cannabis stocks have spent years priced as if permanently impaired—crushed by regulatory risk, punitive taxation and a chronic shortage of capital. Rescheduling would not solve all of these problems, but it would shift a meaningful share of value from the Treasury back to shareholders. Lower taxes raise after-tax cash flows; lower legal risk reduces the cost of capital; both justify higher valuation multiples and revive the case for consolidation.

Plenty of smoke, some fire

Optimism, however, should be rationed. Rescheduling is not legalisation, and the details matter. How the Drug Enforcement Administration interprets Schedule III, how tax authorities manage the transition, and whether future administrations seek to reverse course all remain open questions. State-level restrictions, oversupply in key markets and uneven corporate execution will continue to separate winners from losers.

From pariah to possibility

For now, cannabis investors are once again intoxicated by policy. The recent surge may prove to be little more than a sharp squeeze from deeply depressed levels. Or it may mark the beginning of a long-delayed normalisation of America’s cannabis economy. Either way, a sector long treated as untouchable has rediscovered something it had almost forgotten hope.